Two years after the start of the COVID-19 pandemic, in addition to the vaccines that the world received relatively quickly, there are hundreds of drugs being developed to fight the virus, according to an article in Nature.
“The next three to four months are, we hope, going to be very exciting,” Lawrence Tabak, acting director of the NIH in Bethesda, Maryland told Nature. “Even when a trial does not show efficacy, that’s still incredibly important information. It tells you what not to use.”
“Over the past two years, the ACTIV programme, run by the US National Institutes of Health (NIH), has included more than 30 studies — 13 of them ongoing — of therapeutic agents chosen from a list of 800 candidates. Several of the studies are due to report results in the first half of the year,” the article said. “And that’s just in his (Tabak’s) program; hundreds more are in progress around the world. Whether those results are positive or negative, Tabak says, 2022 is poised to provide some much-needed clarity on how best to treat COVID-19.”